{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-26-000012","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.923188+00:00","generated_at":"2026-05-15T23:28:41.354064+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M","bullets":["Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.","Q4 2025 net loss $54.6M ($1.04 loss per diluted share), vs Q4 2024 loss $31.3M.","Full year 2025 net income $52.6M ($0.93 diluted EPS), vs prior year net loss $190.6M.","Adjusted EBITDA for FY2025 $205.0M, up 12% from $183.1M in 2024.","FY2026 guidance: revenues $720-760M, adjusted net income $25-45M, adjusted EBITDA $135-155M."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-26-000012","json":"https://secwatch.observer/filing/0001367644-26-000012.json","markdown":"https://secwatch.observer/filing/0001367644-26-000012.md","text":"https://secwatch.observer/filing/0001367644-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/0001367644-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:28:41.354064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}